Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Protagonist Therapeutics Inc (NQ: PTGX ) 36.10 UNCHANGED Streaming Delayed Price Updated: 4:00 PM EDT, Jul 22, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Price and Volume Detailed Quote Volume 0 Open 36.10 Bid (Size) 30.30 (1) Ask (Size) 39.59 (1) Prev. Close 36.10 Today's Range 36.10 - 36.10 52wk Range 13.72 - 38.02 Shares Outstanding 58,652,133 Dividend Yield N/A Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year Top News More News Protagonist Therapeutics to Participate in the BTIG Virtual Biotechnology Conference 2024 July 22, 2024 Via ACCESSWIRE 3 Growth Stocks No One Is Watching (But They Should Be) July 11, 2024 While overlooked growth stocks present high risks, it’s difficult to find any other sector with as much upside potential. Via InvestorPlace Performance YTD +54.14% +54.14% 1 Month +12.78% +12.78% 3 Month +35.66% +35.66% 6 Month +44.40% +44.40% 1 Year +84.37% +84.37% More News Read More Protagonist Therapeutics Surges On Plans To Join S&P SmallCap 600 June 28, 2024 Via Investor's Business Daily Topics Stocks Exposures US Equities Protagonist Reports Updated Long Term Results from Rusfertide Phase 2 REVIVE Study at the EHA2024 Congress Showing Durable Hematocrit Control June 13, 2024 Via ACCESSWIRE The 3 Best Biotech Stocks to Buy in June 2024 June 05, 2024 Via InvestorPlace Protagonist Therapeutics to Participate in the Jefferies Global Healthcare Conference 2024 May 31, 2024 Via ACCESSWIRE Protagonist Reports First Quarter 2024 Financial Results and Provides Corporate Update May 07, 2024 Via ACCESSWIRE Protagonist Therapeutics Provides Update on VERIFY Patient Enrollment and Timing of Top-line Data March 26, 2024 Via ACCESSWIRE Protagonist Therapeutics to Participate in Upcoming Investor Conferences March 06, 2024 Via ACCESSWIRE Protagonist Therapeutics Announces Oral Presentation on Long-Term Follow-up of Rusfertide Phase 2 REVIVE Study Open Label Extension at the European Hematology Association 2024 Congress May 14, 2024 Via ACCESSWIRE PTGX Stock Earnings: Protagonist Therapeutics Beats EPS, Beats Revenue for Q1 2024 May 07, 2024 Via InvestorPlace Protagonist Therapeutics to Participate in the Citizens JMP Life Sciences Conference and the Capital One 1st Annual Biotech/Biopharma Disruptors Event May 07, 2024 Via ACCESSWIRE Turnstone Biologics Appoints William Waddill to its Board of Directors April 16, 2024 From Turnstone Biologics Corp. Via GlobeNewswire Protagonist Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update February 27, 2024 Via ACCESSWIRE Protagonist Therapeutics Announces Closing of Worldwide Rusfertide License and Collaboration Agreement with Takeda March 18, 2024 Via ACCESSWIRE Late-Breaking Presentation at American Academy of Dermatology 2024 Annual Meeting Shows that JNJ-2113, the First and Only Investigational Targeted Oral Peptide, Maintained Skin Clearance in Moderate-To-Severe Plaque Psoriasis Through One Year March 11, 2024 Via ACCESSWIRE New England Journal of Medicine Publishes Results of Positive Randomized Phase 2 REVIVE Trial of Rusfertide in Treatment of Polycythemia Vera February 21, 2024 Via ACCESSWIRE Protagonist Therapeutics Reports Granting of Inducement Awards February 20, 2024 Via ACCESSWIRE New England Journal of Medicine Publishes Efficacy and Safety Data of Targeted Oral Peptide JNJ-2113 in a Phase 2b Moderate-To-Severe Plaque Psoriasis Study February 07, 2024 Via ACCESSWIRE Why Is Japanese Drugmaker Takeda Stock Trading Lower Today? February 01, 2024 Via Benzinga 12 Health Care Stocks Moving In Wednesday's After-Market Session January 31, 2024 Via Benzinga Takeda and Protagonist Therapeutics, Inc. Enter into Worldwide License and Collaboration Agreement for Rusfertide, a Late-Stage Rare Hematology Asset January 31, 2024 Via ACCESSWIRE Protagonist Therapeutics to Participate in Fireside Chat at Guggenheim Healthcare Talks 2024 January 29, 2024 Via ACCESSWIRE Protagonist Therapeutics to Participate in the 42nd Annual J.P. Morgan Healthcare Conference January 03, 2024 Via ACCESSWIRE Protagonist Earns $10 Million Payment for Achievement of Clinical Milestone in Phase 2b ANTHEM-UC Study of JNJ-2113 in Adults with Moderately to Severely Active Ulcerative Colitis December 13, 2023 Via ACCESSWIRE Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.